Q1 2024 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2024-05-14 · accession 0000904454-24-000307
$389.9M
Reported value
26
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 530307305 | LBRDK | LIBERTY BROADBAND CORP | $108.0M | 27.7% | 1,886,260 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $29.2M | 7.48% | 592,528 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $26.6M | 6.81% | 175,672 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $22.3M | 5.71% | 539,100 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $21.8M | 5.60% | 677,100 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $20.5M | 5.26% | 158,457 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $19.7M | 5.05% | 50,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $18.1M | 4.65% | 360,916 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $16.7M | 4.28% | 238,046 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $16.2M | 4.16% | 503,759 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $15.5M | 3.99% | 840,453 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $13.6M | 3.48% | 656,600 | Common | SOLE |
| 25470MAF6 | DISH 0 12/15/25 | DISH NETWORK CORPORATION | $13.5M | 3.45% | 18,300,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $12.8M | 3.28% | 961,251 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $12.7M | 3.26% | 1,649,221 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $12.4M | 3.17% | 1,490,170 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $10.0M | 2.56% | 402,400 | Common | SOLE |
| 17144M110 | — | CHURCHILL CAPITAL CORP VII | $175,360 | 0.04% | 548,000 | Common | SOLE |
| G6202B119 | MNYWW | MONEYHERO LIMITED | $108,474 | 0.03% | 895,000 | Common | SOLE |
| 320703101 | — | CALIDI BIOTHERAPEUTICS INC | $70,625 | 0.02% | 125,000 | Common | SOLE |
| 20607U116 | CNDAW | CONCORD ACQUISITION CORP II | $45,447 | 0.01% | 408,333 | Common | SOLE |
| G2476C123 | CDAWF | COMPASS DIGITAL ACQUISITION CORP | $42,311 | 0.01% | 459,906 | Common | SOLE |
| 320703119 | CLDWW | CALIDI BIOTHERAPEUTICS INC | $34,070 | 0.01% | 655,200 | Common | SOLE |
| G63836111 | IVCPW | SWIFTMERGE ACQUISITION CORP | $27,391 | 0.01% | 490,000 | Common | SOLE |
| G9845F117 | LSBWF | YS BIOPHARMA CO LTD | $24,990 | 0.01% | 489,999 | Common | SOLE |
| 56608A113 | — | MARBLEGATE ACQUISITION CORP | $8,232 | 0.00% | 735,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.